BSX Stock Price Today (May 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-05-22
Boston Scientific Corporation (BSX) is trading at $57.78, up 1.10% today (as of May 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $85.19 (47.4% upside).
- Volatility remains elevated (31.89% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (11.60% YoY) alongside significant competitive pressures.
BSX Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $94.32B
P/E Ratio
Forward P/E: 15.10
Revenue Growth
Year over Year
Analyst Target
+47.4% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.59)
- Fundamentals say: Caution warranted (high leverage concerns)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $11.03B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $56.05 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 31.89% annualized volatility and β=0.62, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”
Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
Boston Scientific (NYSE:BSX) reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The FRACTURE trial met all primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use these data to support a regulatory submission for SEISMIQ 4CE. Boston Scientific is a major player in interventional cardiology, with products focused on treating complex coronary and structural heart...
Boston Scientific Corporation (BSX) Fell Due to Weak Results
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street H
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $57.78. The RSI (14-day) is at 55.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $85.19 implies 47.4% upside from current levels. Volatility is moderate at 31.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 23.69, which is in line with broader market averages. The forward P/E is 15.10, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.68, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 3.27. Price-to-Sales is 4.10. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 32 analysts covering BSX, the consensus price target is $85.19. This represents a 47.4% upside from the current price of $57.78. The range spans from a low target of $60.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Moderate volatility (31.9% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $11.03B. The debt-to-equity ratio is 42.25, which is moderate and generally manageable for most companies. The current ratio is 1.90, indicating strong short-term liquidity. The quick ratio is 0.98. The company holds $1.45B in cash and equivalents. Free cash flow is positive at $2.81B, providing a cushion for debt servicing and shareholder returns.